Skip to main content
    A

    ARS Pharmaceuticals, Inc (SPRY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.65
    +0.06 (+1.67%)

    Market Cap: $360.90M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    ARS Pharmaceuticals, Inc (SPRY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    ARS Pharmaceuticals (SPRY) has a market cap of $360.90M and an enterprise value of $457.08M. It kept -163.64% of revenue as net income over the last 12 months. Revenue fell 14.45% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 26.65% above the market cap, as debt exceeds cash.

    Market Cap$360.90M
    Enterprise Value$457.08M
    Latest price (Nov 17, 2026)$3.65

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.38% in the quarter ended Sep 30, 2026 and grew 1.36% a year over 2 years.

    Shares Outstanding99.69M
    Shares Change (YoY)+0.89%
    Shares Change (QoQ)+0.38%
    Share Count Growth (2Y CAGR)+1.36%

    Valuation Ratios

    The price to sales ratio is 3.0x. Its year-end P/S ranged from 11.6x to 292.8x from 2021 to 2025.

    P/S Ratio3.0x
    Forward P/S3.0x

    Price Statistics

    The stock is down 55.54% over 52 weeks and trades 8.75% below its 50-day average.

    Beta (1Y)1.80
    52-Week Change-55.54%
    1-Month Change-13.71%
    3-Month Change-42.79%
    6-Month Change-49.09%
    5-Year Change-60.83%
    Total Return (1Y)-55.54%
    Total Return (3Y CAGR)-8.15%
    Total Return (5Y CAGR)-14.79%
    Return vs SPY (1Y)-60.04%
    Max Drawdown (1Y)-79.71%
    Max Drawdown (3Y)-85.56%
    Sharpe Ratio (1Y)-0.85
    Correlation with SPY (1Y)0.32
    50-Day Average$4.00
    200-Day Average$6.97
    52-Week Range$2.44 to $13.15
    RSI (14 Days)48.5
    Average Volume (20 Days)2.36M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.25x current liabilities.

    Current Ratio3.25x
    Quick Ratio3.07x

    Returns and Efficiency

    Return on invested capital is -143.84% over the last 12 months, against a 5-year average of -5.68%.

    Return on Assets (ROA)-79.48%
    Return on Invested Capital (ROIC)-143.84%
    ROA (5Y Average)-23.72%
    ROIC (5Y Average)-5.68%
    Asset Turnover0.39x
    Inventory Turnover2.40x
    Receivables Turnover2.45x
    Cash Conversion Cycle-501 days

    Scores

    SPRY has an Altman Z-Score of -3.14, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-3.14
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $122.14M over the last 12 months.

    Revenue$122.14M
    Revenue Growth (YoY)-14.45%
    Gross Profit$94.00M
    Operating Income-$197.25M
    Pretax Income-$196.71M
    Net Income-$199.87M
    Reported EPS (TTM)-$2.02

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$25.62M
    Total Debt$121.81M
    Net Debt$96.19M
    Net Debt Per Share$0.96
    Working Capital$146.13M
    Shareholder Equity-$11.96M
    Tangible Book Value-$25.58M
    Total Assets$251.48M
    Total Liabilities$263.44M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$183.07M
    FCF Per Share-$1.84
    Depreciation and Amortization$4.72M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -161.50%.

    Gross Margin76.96%
    Operating Margin-161.50%
    Pretax Margin-161.06%
    Net Margin-163.64%
    Gross Margin (5Y Average)99.78%

    Growth

    Revenue grew 300.09% a year over 3 years.

    Revenue Growth (3Y CAGR)+300.09%
    Book Value Per Share Growth (2Y CAGR)-30.51%
    Tangible Book Per Share Growth (2Y CAGR)-35.05%

    Revenue and profit by year

    Dividends and Yields

    SPRY does not pay a dividend.

    Buyback Yield-1.43%
    Shareholder Yield-1.43%

    Peer Position

    Against 7 similar companies, SPRY has the 6th highest P/S.

    P/S Ratio3.0x vs 4.3x median
    ROIC-143.84% vs -6.52% median
    Revenue Growth (Trailing 4 Quarters, YoY)-14.45% vs +0.70% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 42.06% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+42.06%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SPRY

    What is SPRY's market cap?

    ARS Pharmaceuticals has a market cap of $360.90M. Its enterprise value, which adds debt and subtracts cash, is $457.08M.

    How many shares of SPRY are outstanding?

    ARS Pharmaceuticals has 99.69M shares outstanding. The count is up 0.89% from a year earlier.

    Does SPRY pay a dividend?

    No. ARS Pharmaceuticals does not pay a dividend.

    How much debt does SPRY have?

    ARS Pharmaceuticals has $121.81M of total debt and $25.62M of cash and equivalents, a net debt position of $96.19M.